Filter posts

BIO’s Dave Thomas Talks VC Funding with Daniel Levine

Last week, BIO Industry Analysis’s Dave Thomas spoke with Daniel Levine for his weekly podcast, …

BIO’s Next Generation Partnering System to Open April 2015

You’ve found your lead investor. Now it’s time to get to the next stage, and …

The Perfect Close

With a fast and furious finish, yesterday, March 2nd, the Nasdaq Composite (IXIC) closed at …

Choose Wisely My Friend- Survey Says, Identifying the Right R&D Partner is the Most Challenging Aspe...

A recent survey conducted by BIO confirms the increasing reliance on R&D outsourcing as biotech and pharmaceutical companies indicate speed, flexibility, …

Kyle Bass Files Second IPR Petition

Today hedge fund manager Kyle Bass has continued his reported “short activist strategy” campaign by …

BIO Accepting Nominations for its Award Honoring One Outstanding Woman in Industrial Biotech

Today, BIO announced that it has officially extended its deadline for the Rosalind Franklin Award for …

Nasdaq Social Bell: Twitter Strategies For Biotechs

Last week at the BIO CEO & Investor Conference in New York City, I had …

Deal Structures: More Options for Companies

By most measures, 2014 was a great year for the biotechnology industry. Venture capital deal …

Ten Years of Therapeutic Venture Capital

What therapeutic areas have received the most funding in private drug companies over the last …

Dow Jones VentureWire: BIO Report on Venture Funding for Therapeutic Innovation

Today, Brian Gormley’s story – Biotech VCs Shift Away From Chronic Diseases, Report Says – …